Masato Tarumi, Nobuya Abe, Tatsuya Atsumi.
Progressive cognitive dysfunction with subdural polycystic hygroma and systemic inflammation under immunosuppressive therapy.
Int J Rheum Dis 2023, in press.
IF: 2.558
{ 128件 }
Masato Tarumi, Nobuya Abe, Tatsuya Atsumi.
Progressive cognitive dysfunction with subdural polycystic hygroma and systemic inflammation under immunosuppressive therapy.
Int J Rheum Dis 2023, in press.
IF: 2.558
Nakamura J, Tsujino I, Shima H, Nakaya T, Sugimoto A, Sato T, Watanabe T, Ohira H, Suzuki M, Tsuneta S, Hisada R, Kato M, Konno S.
Clinical and hemodynamic response to imatinib in pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis: a pilot study of five cases.
American Journal of Cardiovascular Drugs. in press.
IF= 3.290
Aso K, Kono M, Kanda M, Kudo Y, Sakiyama K, Hisada R, Karino K, Ueda Y, Nakazawa D, Fujieda Y, Kato M, Amengual O and Atsumi T.
Itaconate ameliorates autoimmunity by modulating T cell imbalance via metabolic and epigenetic reprogramming.
Nature Commun. in press.
令和4年度 北海道大学大学院医学研究院 優秀論文賞 阿部 靖矢先生
令和4年度 北海道大学大学院医学研究院 優秀論文賞 狩野 皓平先生
Karino K, Kono M, Kanda M, Atsumi T.
Reply.
Arthritis Rheumatol. in press.
IF=15.483
Kato M, Ninagawa K, Atsumi T.
Comment on: Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study: Reply.
Rheumatology (Oxford). in press
IF=7.046
Aso K, Fujieda Y, Atsumi T.
Homonymous hemianopsia and headache with mass-like lesion Annals of the Rheumatic Diseases.
IF 19.103
Scherlinger M, Pan W, Hisada R, Boulougoura A, Yoshida N, Vukelic M, Umeda M, Krishfield S, Tsokos MG, Tsokos GC.
Phosphofructokinase P fine-tunes T regulatory cell metabolism, function, and stability in systemic autoimmunity.
Sci Adv. 2022;8(48):eadc9657.
IF = 14.980
Nagasaka K, Amano K, Dobashi H, Nagafuchi H, Sada K, Komagata Y, Yamamura M, Kato M, Endo T, Nakaya I, Takeuchi T, Murakawa Y, Sugihara T, Saito M, Hayashi T, Furuta S, Tamura N, Karasawa K, Banno S, Endo S, Majima M, Kaname S, Arimura Y, Harigai M.
Nation-wide Cohort Study of Remission Induction Therapy using Rituximab in Japanese patients with ANCA-Associated Vasculitis:
effectiveness and safety in the first six months.
Modern Rheumatology. in press.
IF: 2.862